Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2017’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)

The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlists all their major and minor projects

The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ache Laboratorios Farmaceuticos SA

Achillion Pharmaceuticals Inc

Adamis Pharmaceuticals Corp

Advanced Inhalation Therapies (AIT) Ltd

AlgiPharma AS

Allinky Biopharma

Angiocrine Bioscience Inc

Angion Biomedica Corp

apceth Biopharma GmbH

Arch Biopartners Inc

Aridis Pharmaceuticals LLC

Astellas Pharma Inc

AstraZeneca Plc

Axikin Pharmaceuticals Inc

Bayer AG

Beech Tree Labs Inc

Bioneer Corp

Boehringer Ingelheim GmbH

C4X Discovery Holdings PLC

Carolus Therapeutics Inc

Cellular Biomedicine Group Inc

Celon Pharma SA

Chiesi Farmaceutici SpA

China Resources Pharmaceutical Group Ltd

Cipla Ltd

Circassia Pharmaceuticals Plc

CSL Ltd

Cytokinetics Inc

Daiichi Sankyo Co Ltd

Diffusion Pharmaceuticals Inc

Domainex Ltd

Enterprise Therapeutics Ltd

Errant Gene Therapeutics LLC

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals LLC

Galapagos NV

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Grifols SA

Hanmi Pharmaceuticals Co Ltd

Humanigen Inc

iCeutica Inc

InMed Pharmaceuticals Inc

Insmed Inc

Intech Biopharm Ltd

Invion Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Johnson & Johnson

Kissei Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

MedImmune LLC

Mereo Biopharma Group Plc

Meridigen Biotech Co Ltd

Microbion Corp

Novartis AG

OncBioMune Pharmaceuticals Inc

OPKO Health Inc

Orchid Pharma Ltd

Orion Corporation

Pfizer Inc

Pharmaxis Ltd

Promedior Inc

ProMetic Life Sciences Inc

Proteostasis Therapeutics Inc

Pulmagen Therapeutics LLP

Pulmatrix Inc

Pulmotect Inc

Qu Biologics Inc

Quark Pharmaceuticals Inc

Re-Pharm Ltd

Regeneron Pharmaceuticals Inc

Respira Therapeutics Inc

Respiratorius AB

rEVO Biologics Inc

Rhizen Pharmaceuticals SA

SATT North SAS

SolAeroMed Inc

sterna biologicals Gmbh & Co KG

Sun Pharmaceutical Industries Ltd

Sunovion Pharmaceuticals Inc

Synairgen Plc

Synovo GmbH

Syntrix Biosystems Inc

Teva Pharmaceutical Industries Ltd

Therabron Therapeutics Inc

Theravance Biopharma Inc

Torrent Pharmaceuticals Ltd

Unizyme Laboratories A/S

Vectura Group Plc

Verona Pharma Plc

Yuhan Corp

Yungjin Pharm Co Ltd

Zai Lab Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Chronic Obstructive Pulmonary Disease (COPD) - Overview 7

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development 8

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 30

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 46

Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles 92

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 437

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 452

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 456

Appendix 475

List of Tables

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Achillion Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Adamis Pharmaceuticals Corp, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AlgiPharma AS, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Allinky Biopharma, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Angiocrine Bioscience Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Angion Biomedica Corp, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by apceth Biopharma GmbH, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Arch Biopartners Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Aridis Pharmaceuticals LLC, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Astellas Pharma Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AstraZeneca Plc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Axikin Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Bayer AG, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Beech Tree Labs Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Bioneer Corp, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by C4X Discovery Holdings PLC, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Carolus Therapeutics Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Cellular Biomedicine Group Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Celon Pharma SA, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Chiesi Farmaceutici SpA, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by China Resources Pharmaceutical Group Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Cipla Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Circassia Pharmaceuticals Plc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by CSL Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Cytokinetics Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Diffusion Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Domainex Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Enterprise Therapeutics Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Errant Gene Therapeutics LLC, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Foresee Pharmaceuticals LLC, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Galapagos NV, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Gilead Sciences Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by GlaxoSmithKline Plc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Grifols SA, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Humanigen Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by iCeutica Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by InMed Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Insmed Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Intech Biopharm Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Invion Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Johnson & Johnson, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by MedImmune LLC, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Mereo Biopharma Group Plc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Meridigen Biotech Co Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Microbion Corp, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Novartis AG, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by OncBioMune Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by OPKO Health Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Orchid Pharma Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Orion Corporation, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pfizer Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pharmaxis Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Promedior Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by ProMetic Life Sciences Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Proteostasis Therapeutics Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pulmagen Therapeutics LLP, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pulmatrix Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pulmotect Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Qu Biologics Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Quark Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Re-Pharm Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Respira Therapeutics Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Respiratorius AB, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by rEVO Biologics Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Rhizen Pharmaceuticals SA, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by SATT North SAS, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by SolAeroMed Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by sterna biologicals Gmbh & Co KG, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sun Pharmaceutical Industries Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sunovion Pharmaceuticals Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Synairgen Plc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Synovo GmbH, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Syntrix Biosystems Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Therabron Therapeutics Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Theravance Biopharma Inc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Torrent Pharmaceuticals Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Unizyme Laboratories A/S, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Vectura Group Plc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Verona Pharma Plc, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Yuhan Corp, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Yungjin Pharm Co Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Zai Lab Ltd, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..3), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..4), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..5), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..6), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..7), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..8), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..9), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..10), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..11), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..12), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2017 (Contd..13), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products, H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products, H2 2017 (Contd..1), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products, H2 2017 (Contd..2), H2 2017

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products, H2 2017 (Contd..3), H2 2017

List of Figures

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports